Clinical Research Directory
Browse clinical research sites, groups, and studies.
Transvaginal Botulinum Toxin A for Interstitial Cystitis / Bladder Pain Syndrome
Sponsor: Stanford University
Summary
Interstitial cystitis / bladder pain syndrome (IC/BPS) is a debilitating condition that affects millions of women in the United States. Women suffer from recurring pelvic pain, bladder pressure, painful bladder, urinary frequency (needing to go often) and urgency (feeling a strong need to go). Women are five times more likely to suffer from IC/BPS than men. IC/BPS is a common cause of painful bladder after excluding urinary tract infection. About one-third of women resort to opioids, thus contributing to the current opioid crisis. Sadly, there are no durable treatments and the majority of therapies are not FDA-approved for IC/BPS.
Official title: T3STOPBPS: Open Label Clinical Trial of Transvaginal Trigone Treatment (T3) With Botulinum Toxin A (BTA) for Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
5
Start Date
2022-04-04
Completion Date
2025-02-28
Last Updated
2024-04-19
Healthy Volunteers
No
Interventions
Transvaginal botulinum toxin A (BTA) injection
Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
Locations (1)
Urology Clinic (Stanford University), 1000 Welch Road, Suite 100
Palo Alto, California, United States